X
Request a Rep
By completing this form, you are agreeing to receive communications from Pharming Healthcare Inc., its affiliates, and their agents and representatives. You may opt out at any time.
By completing this form, you are agreeing to receive communications from Pharming Healthcare Inc., its affiliates, and their agents and representatives. You may opt out at any time.
Indications and Usage
JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Important Safety Information
Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA.
JOENJA may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with JOENJA and for 1 week after the last dose of JOENJA.
Live, attenuated vaccinations may be less effective if administered during JOENJA treatment.
Use of JOENJA in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients weighing less than 45 kg.
The most common adverse reactions (incidence >10%) seen in clinical trials were headache, sinusitis, and atopic dermatitis.
Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL. No patients developed an ANC <500 cells/ microL and there were no reports of infection associated with neutropenia.
Before prescribing JOENJA, please read the full Prescribing Information.
